CA-IKOTEK
Ikotek, the leading IoT original design manufacturer (ODM) and electronics manufacturing service (EMS) provider, is announcing expansion of its executive management team with industry veterans and continue their aggressive growth plans for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005870/en/
Ikotek - Your Trusted IoT ODM Partner (Photo: Business Wire)
Headquartered in San Diego, USA, Ikotek offers a one-stop-shop for IoT solutions across design and development, hardware build, testing and verification, product validation, software development, manufacturing and certification delivering high quality products and services to reduce complexity, speed up time to market, eliminate risk and reduce costs. The company has already designed, manufactured and shipped millions of IoT devices since its inception.
Ikotek, the only US-based global ODM with a pure IoT focus, combines end-to-end design consultancy across program management, R&D, sourcing, testing and production at its own as well as third party manufacturing facilities to produce designs for our customers. With a wide variety IoT projects in progress, such as asset tracking, dash cameras, PDAs and handhelds, point of sale (POS) devices and hardware for smart grid and metering deployments, Ikotek’s core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT at scale.
Led by Chief Executive Officer, Joe Peterson, who has more than 27 years of diverse experience across cellular and IoT industries in the US and international, Ikotek has gathered a team of industry veterans to amplify its vision of becoming the world’s most trusted IoT ODM. Recent additions to the US-based executive management team include:
Bill Leunis, the Vice President of Finance, who brings extensive experience in finance, operations and general management in manufacturing and EMS organizations. Previously, he has headed Finance in divisions of large multi-national corporations ranging in size from 500 to 20,000 people. In addition, he has served as CFO of a company, leading all aspects from its acquisition to IPO for eight years after going public.
Tim Newberg, the Vice President of Sales for the US and Canada, has joined with more than 25 years of experience and leadership in the wireless, broadband, consumer electronics and massive IoT industries. From hardware and software strategy to product marketing, sales and business development he has held senior executive positions at companies including Texas Instruments, Broadcom, Sequans, Rootmetrics, Polte and Sercomm.
Steve Burrington, the Head of North America Engineering, is a 25-year veteran of large and medium-sized wireless product development teams. Previously he served as Vice President of Engineering at CalAmp for the company’s telematics products. He has extensive experience of getting a diverse range of products to market, via organic development and JDM partnerships. In addition, he has held Vice President of Engineering roles at Netgear and Sierra Wireless.
These additions to the Ikotek management team have been supported by hires across the business and Ikotek now has more than 350 dedicated R&D employees and continues to add employees on a weekly basis.
“We’ve seen an incredible uptake of new customers over the last year and we’re excited to bring our unique ODM capabilities and advantages to customers,” said Peterson. “Supporting our customers with quick time-to-market, leading IoT industry expertise and cost-effective services and solutions is critical during a time where digital transformation is growing across all industries. To help manage growth, commercial excellence and new customers, I’m thrilled to welcome these three leading IoT and ODM capacities to our management team. We aim to serve our customers with local experts in North America and Europe and APAC so we can ensure that Ikotek is close to our customers and has local understanding of their needs.”
Ikotek targets mid-market IoT customers in response to increased demand for the design and build of products. The company’s ethos is to give customers a competitive advantage, through cost reductions and enable substantial savings to be achieved on their device design, manufacturing and certification costs. In addition, Ikotek is focused on taking customers’ projects from idea to market in record breaking time. In less than three months, Ikotek has provided end-to-end ODM services that took a complex IoT device to market including design, development and manufacturing.
“Ikotek exists to turn our customers’ device dreams into IoT reality,” Peterson added, pointing out the ways in which the company can help are listed on www.ikotek.com. “We’re keen to become customers’ indispensable partner in taking their innovations from concept to high volume product launches across global markets.”
About Ikotek
Ikotek is The IoT ODM. With a wide variety IoT projects currently underway, our core focus is on the enterprise market as it looks to develop solutions to take full advantage of IoT. We cover technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom